Methicillin-Resistant Staphylococcus Aureus | Pharmacor | G7 | 2015

Last Updated 29 December 2015
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The recent approvals of oritavancin (The Medicine Company’s Orbactiv), dalbavancin (Allergan’s Dalvance/Xydalba), and tedizolid (Bayer HealthCare/Merck’s Sivextro) have greatly increased treatment options for MRSA infections, making the hospital-treated MRSA market highly competitive. Within this crowded space, new agents will need to demonstrate improvement over current therapies and justify their premium pricing in light of significant competition, including generics. This report provides a comprehensive overview and analysis of the epidemiology, patient populations, and current and emerging medical practice and therapies for MRSA in the major pharmaceutical markets. The insights presented in this report are derived from primary and secondary research, company presentations and sales data, as well as detailed interviews with recognized key opinion leaders (KOLs). This report includes a 2014-2024, epidemiology-based, annualized, bottom-up forecast of current and emerging MRSA therapies in the major pharmaceutical markets.